Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study

Blood (2019) 134 (Supplement_1): 830.

https://doi.org/10.1182/blood-2019-131494

Published: 2019

Journal Articles

Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS

Eric Huselton, MD, Amanda F Cashen, MD, John F. DiPersio, MD PhD, Meagan Jacoby, MD, Iskra Pusic, MD, Rizwan Romee, MD PhD, Mark A. Schroeder, MD, Geoffrey L. Uy, MD, Peter Westervelt, MD PhD

Blood (2019) 134 (Supplement_1): 3915.

https://doi.org/10.1182/blood-2019-132065

Published: 2019

Journal Articles

An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicity Risk

Catherine Diefenbach, MD, Sarit Assouline, MD, Francesc Bosch, MD PhD, Chan Y. Cheah, Won Seog Kim, MD PhD, Matthew J Matasar, MD, Carlos Panizo, MD PhD, Dok Hyun Yoon, MD PhD, Brendan Bender, PhD, Genevive Hernandez, PhD, Chi-Chung Li, PhD, Bruce McCall, MD, Carol O'Hear, MD PhD, Michael C Wei, MD PhD, Shen Yin, PhD, Kasra Yousefi, MSc, Antonia Kwan, MD PhD MRCPCH, Loretta J. Nastoupil, MD MSc

Blood (2019) 134 (Supplement_1): 4728.

https://doi.org/10.1182/blood-2019-123757

Published: 2019

Journal Articles

Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML)

Amy Wang, MD MPH, Howard Weiner, Richard A. Larson, MD, Olatoyosi Odenike, MD, Andrew S Artz, MD, Michael R. Bishop, MD, Lucy Godley, MD PhD, Michael Thirman, MD, Satyajit Kosuri, MD, Jane Churpek, MD, Emily K Curran, MD, Kristen Pettit, MD, Wendy Stock, MD, Hongtao Liu, MD PhD

Blood (2018) 132 (Supplement 1): 4073.

https://doi.org/10.1182/blood-2018-99-120244

Published: 2018

Journal Articles

MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m 2 ) in Combination with Lenalidomide and Dexamethasone

Blood (2018) 132 (Supplement 1): 1983.

https://doi.org/10.1182/blood-2018-99-117120

Published: 2018

Journal Articles

A Phase II of Combination Daunorubicin and Cytarabine (Ara-C) and Nilotinib (TASIGNA) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Final Results

Aref Al-Kali, MD, Raoul Tibes, MD PhD, Jeanne Palmer, MD, Hassan B. Alkhateeb, MD, Mrinal M. Patnaik, MD MBBS, Kebede H. Begna, MD, Naseema Gangat, MBBS, Pamela Atherton, Shujun Liu, PhD, Rong He, MD, Shahrukh K. Hashmi, MD MPH, Mark R. Litzow, MD

Blood (2018) 132 (Supplement 1): 1443.

https://doi.org/10.1182/blood-2018-99-118552

Published: 2018

Journal Articles

Individual Patient Dose-Escalated Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Vs.-Host Disease in Children and Adults: Safety, Efficacy and Immune Correlates

Blood (2017) 130 (Supplement 1): 3248.

https://doi.org/10.1182/blood.V130.Suppl_1.3248.3248

Published: 2017

Journal Articles

A Phase I Trial of 90 Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma

Sherilyn A Tuazon, MD, Brenda M. Sandmaier, MD, Johnnie J. Orozco, MD PhD, Ajay K. Gopal, MD, Leona A. Holmberg, MD PhD, Pamela S. Becker, MD PhD, Sally J. Lundberg, Brian G. Till, MD, Margaret E. Nartea, Ted Gooley, PhD, Darrell R. Fisher, PhD, Joseph G. Rajendran, MD, Oliver W. Press, MD PhD, William I. Bensinger, MD, Damian J. Green, MD

Blood (2017) 130 (Supplement 1): 910.

https://doi.org/10.1182/blood.V130.Suppl_1.910.910

Published: 2017

Journal Articles

Comparative Risk Assessment of Imatinib, Nilotinib and Dasatinib in Randomized Controlled Trials: A Meta-Analysis

Ahmad Ghorab, MDMSc, Hagop M. Kantarjian, MD, Hesham Elhalawani, MD MS, Hoda Ahmed, MD MS, Ahmed Essam, MD, Omar Abdel-Rahman, MD PhD, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 2869.

https://doi.org/10.1182/blood.V130.Suppl_1.2869.2869

Published: 2017

Journal Articles

Bendamustine, Carfilzomib, and Melphalan (BCM) Conditioning Prior to Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Feasibility Study

A. Samer Al-Homsi, MD, Marlee Muilenburg, BSN, Kelli Cole, MSN, Muneer H. Abidi, MD, Stephanie F. Williams, MD

Blood (2016) 128 (22): 4635.

https://doi.org/10.1182/blood.V128.22.4635.4635

Published: 2016

Journal Articles

A Phase I Study of the Multi-Targeted Tyrosine Kinase Inhibitor Cabozantinib in Patients with Acute Myeloid Leukemia

Amir T. Fathi, MD, Traci M. Blonquist, MS, Mark J. Levis, MD PhD, Daniela Hernandez, MD, Karen K. Ballen, MD, David E. Avigan, MD, Robin Joyce, MD, Malgorzata McMasters, MD, Emma Logan, Gabriela S. Hobbs, MD, Andrew M. Brunner, MD, Christine Connolly, Ashley M. Perry, BS, Christelle Joseph, Tina T. Som, Aura Y. Ramos, Donna S. Neuberg, ScD, Philip C. Amrein, MD

Blood (2016) 128 (22): 5218.

https://doi.org/10.1182/blood.V128.22.5218.5218

Published: 2016

Journal Articles

A Phase II of Combination D aunorubicin and Cytarabine ( A ra-c) and Nilotinib ( TA signa) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Interim Results

Aref Al-Kali, MD, Raoul Tibes, MD PhD, Jeanne Palmer, MD, Hassan B Alkhateeb, MD, Pamela Atherton, Fei Yan, Shujun Liu, PhD, Rong He, MD, Shahrukh K. Hashmi, MD, Mark R Litzow, MD

Blood (2015) 126 (23): 3808.

https://doi.org/10.1182/blood.V126.23.3808.3808

Published: 2015

Journal Articles

Safety of Multiple Doses of CAR T Cells

Rayne H. Rouce, MD, Kristen Fousek, Nabil Ahmed, MD, Stephen Gottschalk, MD, Barbara Savoldo, MD, Gianpietro Dotti, MD, Carlos A. Ramos, MD, Chrystal Louis, MD, Cliona M. Rooney, PhD, Malcolm K. Brenner, MD PhD, Helen E. Heslop, MD

Blood (2015) 126 (23): 4425.

https://doi.org/10.1182/blood.V126.23.4425.4425

Published: 2015

Journal Articles

Readmission Rates Due To Venous Thromboembolism In Cancer Patients After Abdominopelvic Surgery

Christine Klimowicz White, DO, Jessica Langholtz, Zackory T. Burns, Susan Kruse Sullivan, Kimberly Sallee, David H. Henry, MD

Blood (2013) 122 (21): 2940.

https://doi.org/10.1182/blood.V122.21.2940.2940

Published: 2013

Journal Articles

Phase II Clinical and Correlative Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRD-R) Induces High Rates Of MRD Negativity In Newly Diagnosed Multiple Myeloma (MM) Patients

Blood (2013) 122 (21): 538.

https://doi.org/10.1182/blood.V122.21.538.538

Published: 2013

Journal Articles

Human Polyomaviruses Were Not Detected in Cerebrospinal Fluid of Patients with Neurological Complications After Hematopoetic Stem Cell Transplantation

Britt Gustafsson, Sr., Rubin Johanna, Peter Priftakis, Jr., Geraldine Giraud, Torbjorn Ramqvist, Tina Dalianis, Sr.

Blood (2012) 120 (21): 4503.

https://doi.org/10.1182/blood.V120.21.4503.4503

Published: 2012

Journal Articles

Pilot Study: Favorable Outcomes with Addition of Topotecan to Busulfan/Melphalan As High-Dose Myeloablative Therapy Followed by Autologous Hematopoietic Cell Transplantation

Joseph Rosenthal, MD, Anna Pawlowska, MD, Jerry Cheng, MD, Steven Kechichian, Debbie Hitt, Mary Suarez, Ni-Chun Tsai, MS MPH, Joycelynne Palmer, PHD

Blood (2012) 120 (21): 4553.

https://doi.org/10.1182/blood.V120.21.4553.4553

Published: 2012

Journal Articles

Efficacy and Safety of Micafungin for the Prophylaxis of Invasive Fungal Disease During Neutropenia in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2012) 120 (21): 1932.

https://doi.org/10.1182/blood.V120.21.1932.1932

Published: 2012

Journal Articles

Cyclosporine Taper Does Not Prevent Relapse in Severe Aplastic Anemia

Phillip Scheinberg, MD, Olga Nunez, RN, Priscila Scheinberg, MS, CCRP, Barbara Weinstein, RN, Colin O. Wu, PhD, Neal S. Young, MD

Blood (2011) 118 (21): 2406.

https://doi.org/10.1182/blood.V118.21.2406.2406

Published: 2011

Journal Articles

Total Therapy 6: Initial Results of Dose-Dense Strategy for Previously Treated Multiple Myeloma

Saad Usmani, MD, FACP, Alan Mitchell, Bijay Nair, MD, Sarah Waheed, MD, Frits van Rhee, MD, PhD, Yazan Alsayed, MD, Nathan M Petty, Doug Steward, Susan Panozzo, Antje Hoering, PhD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2011) 118 (21): 3081.

https://doi.org/10.1182/blood.V118.21.3081.3081

Published: 2011

NARROW

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study

Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS

An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicity Risk

Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML)

MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m 2 ) in Combination with Lenalidomide and Dexamethasone

A Phase II of Combination Daunorubicin and Cytarabine (Ara-C) and Nilotinib (TASIGNA) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Final Results

Individual Patient Dose-Escalated Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Vs.-Host Disease in Children and Adults: Safety, Efficacy and Immune Correlates

A Phase I Trial of 90 Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma

Comparative Risk Assessment of Imatinib, Nilotinib and Dasatinib in Randomized Controlled Trials: A Meta-Analysis

Bendamustine, Carfilzomib, and Melphalan (BCM) Conditioning Prior to Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Feasibility Study

A Phase I Study of the Multi-Targeted Tyrosine Kinase Inhibitor Cabozantinib in Patients with Acute Myeloid Leukemia

A Phase II of Combination D aunorubicin and Cytarabine ( A ra-c) and Nilotinib ( TA signa) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Interim Results

Safety of Multiple Doses of CAR T Cells

Readmission Rates Due To Venous Thromboembolism In Cancer Patients After Abdominopelvic Surgery

Phase II Clinical and Correlative Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRD-R) Induces High Rates Of MRD Negativity In Newly Diagnosed Multiple Myeloma (MM) Patients

Human Polyomaviruses Were Not Detected in Cerebrospinal Fluid of Patients with Neurological Complications After Hematopoetic Stem Cell Transplantation

Pilot Study: Favorable Outcomes with Addition of Topotecan to Busulfan/Melphalan As High-Dose Myeloablative Therapy Followed by Autologous Hematopoietic Cell Transplantation

Efficacy and Safety of Micafungin for the Prophylaxis of Invasive Fungal Disease During Neutropenia in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Cyclosporine Taper Does Not Prevent Relapse in Severe Aplastic Anemia

Total Therapy 6: Initial Results of Dose-Dense Strategy for Previously Treated Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only